Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04638881 · ClinicalTrials.gov registry record · Phase 2
Magnesium for Peroral Endoscopic Myotomy
A Phase 2 study of Esophageal Spasm, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT04638881 is a Phase 2 study of Esophageal Spasm that has completed, run by Stanford University. The registered enrollment target is 92 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04638881, a Phase 2 study of Esophageal Spasm, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
Postoperative pain after peroral endoscopic myotomy occurs due to involuntary esophageal smooth muscle spasms. Magnesium has antispasmodic properties as a smooth muscle relaxant. This study hypothesizes that among patients having peroral endoscopic myotomy, magnesium will decrease postoperative esophgeal pain as measured by the esophageal symptoms questionnaire, while decreasing perioperative opioid requirements.
Conditions Studied
Interventions
- DRUG Magnesium sulfate
- DRUG Normal Saline
Study Locations (1)
California
- Stanford Health Care - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2020-12-28 |
| Est. Completion | 2023-04-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04638881
The ClinicalTrials.gov registry entry for NCT04638881 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Spasm appearing as the primary indexed condition, and to 2 interventions - of which Magnesium sulfate is the first listed.
NCT04638881 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04638881 about?
NCT04638881 is a clinical study titled "Magnesium for Peroral Endoscopic Myotomy". Postoperative pain after peroral endoscopic myotomy occurs due to involuntary esophageal smooth muscle spasms. Magnesium has antispasmodic properties as a smooth muscle relaxant. This study hypothesizes that among patients having peroral endoscopic myotomy, magnesium will decrease postoperative esop...
What is the current status of trial NCT04638881?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2020-12-28. Estimated completion is 2023-04-13.
What conditions does trial NCT04638881 study?
This clinical trial studies the following conditions: Esophageal Spasm.
What interventions are being tested in trial NCT04638881?
The interventions under investigation include: Magnesium sulfate (DRUG), Normal Saline (DRUG).
Who is sponsoring clinical trial NCT04638881?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04638881 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.